Drug
Rituximab
Rituximab: highest development phase Phase 3, developed by Bayer, Biogen, Genmab and others. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bayer, Biogen, Genmab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rituximab NCT04743739 | Phase 3 | Idiopathic Membranous Nephropathy |
| Rituximab NCT01118234 | Phase 3 | Chronic Lymphocytic Leukemia |
| Rituximab NCT00443651 | Phase 3 | Rheumatoid Arthritis |
| Rituximab NCT07731789 | Phase 2 | Classic Follicular Lymphoma |
| rituximab NCT00031642 | Phase 1/2 | Lymphoma |
| Rituximab NCT00807196 | Phase 1/2 | Non-Hodgkins Lymphoma |
| rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone NCT04663347 | Phase 1/2 | Diffuse Large B-Cell Lymphoma |
Latest
No recent events.
Follow Rituximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.